Ilsung Is Co., Ltd. (KRX:003120)
15,550
+50 (0.32%)
Feb 12, 2025, 9:00 AM KST
Ilsung Is Revenue
Ilsung Is had revenue of 19.02B KRW in the quarter ending September 30, 2024, with 5.23% growth. This brings the company's revenue in the last twelve months to 74.17B, up 1.35% year-over-year. In the year 2023, Ilsung Is had annual revenue of 78.05B with 27.44% growth.
Revenue (ttm)
74.17B
Revenue Growth
+1.35%
P/S Ratio
1.42
Revenue / Employee
n/a
Employees
n/a
Market Cap
108.30B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 78.05B | 16.81B | 27.44% |
Dec 31, 2022 | 61.25B | 19.16B | 45.52% |
Dec 31, 2021 | 42.09B | 1.49B | 3.67% |
Dec 31, 2020 | 40.60B | -7.81B | -16.13% |
Dec 31, 2019 | 48.41B | -13.24B | -21.48% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,364.39B |
Celltrion | 2,876.25B |
Yuhan | 2,008.84B |
SK Biopharmaceuticals | 511.33B |
SK bioscience | 201.30B |
Hanmi Pharm. | 1,495.50B |
Peptron | 2.41B |
Hanall Biopharma | 134.24B |